CAR T-cells merge into the fast lane of cancer care

被引：39

作者：

Frey, Noelle V. ^{[1
]}

Porter, David L. ^{[1
]}

机构：

[1] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2016年 / 91卷 / 01期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; CHIMERIC ANTIGEN RECEPTOR; TERM-FOLLOW-UP; LYMPHOCYTIC-LEUKEMIA; RELAPSE; CHEMOTHERAPY; LYMPHOMA; SURVIVAL; ADULTS; TRANSPLANTATION;

D O I：

10.1002/ajh.24238

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chimeric antigen receptors (CARs) can be introduced into T-cells redirecting them to target specific tumor antigens. CAR-modified T cells targeting CD19 have shown remarkable activity against CD19+ malignancies including B cell acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphomas (NHL). Complete remission rates as high as 90% have been observed for patients with relapsed and refractory ALL and greater than 50% response rates have been seen in heavily pre-treated CLL and NHL. Excitingly, some remissions have been durable without any additional therapy, a finding which correlates with in-vivo T-cell persistence and B-cell aplasia. The major treatment related toxicities include B-cell aplasia, neurologic toxicities, and a potentially severe cytokine release syndrome. This review summarizes outcomes for patients treated with CD19-CAR T-cells while exploring the field's challenges and future directions. (c) 2015 Wiley Periodicals, Inc.

引用

页码：146 / 150

页数：5

共 37 条

[1] Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study [J].

Annino, L ;

Vegna, ML ;

Camera, A ;

Specchia, G ;

Visani, G ;

Fioritoni, G ;

Ferrara, F ;

Peta, A ;

Ciolli, S ;

Deplano, W ;

Fabbiano, F ;

Sica, S ;

Di Raimondo, F ;

Cascavilla, N ;

Tabilio, A ;

Leoni, P ;

Invernizzi, R ;

Baccarani, M ;

Rotoli, B ;

Amadori, S ;

Mandelli, F .

BLOOD, 2002, 99 (03) :863-871

[2] Toxicity management for patients receiving novel T-cell engaging therapies [J].

Barrett, David M. ;

Teachey, David T. ;

Grupp, Stephan A. .

CURRENT OPINION IN PEDIATRICS, 2014, 26 (01) :43-49

[3] Relapsed childhood acute lymphoblastic leukaemia [J].

Bhojwani, Deepa ;

Pui, Ching-Hon .

LANCET ONCOLOGY, 2013, 14 (06) :E205-E217

[4] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias [J].

Brentjens, Renier J. ;

Riviere, Isabelle ;

Park, Jae H. ;

Davila, Marco L. ;

Wang, Xiuyan ;

Stefanski, Jolanta ;

Taylor, Clare ;

Yeh, Raymond ;

Bartido, Shirley ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Bernal, Yvette ;

Pegram, Hollie ;

Przybylowski, Mark ;

Hollyman, Daniel ;

Usachenko, Yelena ;

Pirraglia, Domenick ;

Hosey, James ;

Santos, Elmer ;

Halton, Elizabeth ;

Maslak, Peter ;

Scheinberg, David ;

Jurcic, Joseph ;

Heaney, Mark ;

Heller, Glenn ;

Frattini, Mark ;

Sadelain, Michel .

BLOOD, 2011, 118 (18) :4817-4828

[5] Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL [J].

Christopoulos, Petros ;

Pfeifer, Dietmar ;

Bartholome, Kilian ;

Follo, Marie ;

Timmer, Jens ;

Fisch, Paul ;

Veelken, Hendrik .

BLOOD, 2011, 117 (14) :3836-3846

[6] Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].

Davila, Marco L. ;

Riviere, Isabelle ;

Wang, Xiuyan ;

Bartido, Shirley ;

Park, Jae ;

Curran, Kevin ;

Chung, Stephen S. ;

Stefanski, Jolanta ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Fink, Mitsu ;

Shinglot, Himaly ;

Youssif, Maher ;

Satter, Mark ;

Wang, Yongzeng ;

Hosey, James ;

Quintanilla, Hilda ;

Halton, Elizabeth ;

Bernal, Yvette ;

Bouhassira, Diana C. G. ;

Arcila, Maria E. ;

Gonen, Mithat ;

Roboz, Gail J. ;

Maslak, Peter ;

Douer, Dan ;

Frattini, Mark G. ;

Giralt, Sergio ;

Sadelain, Michel ;

Brentjens, Renier .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[7] Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? [J].

Dreger, Peter ;

Schetelig, Johannes ;

Andersen, Niels ;

Corradini, Paolo ;

van Gelder, Michel ;

Gribben, John ;

Kimby, Eva ;

Michallet, Mauricette ;

Moreno, Carol ;

Stilgenbauer, Stephan ;

Montserrat, Emili .

BLOOD, 2014, 124 (26) :3841-3849

[8] Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study [J].

Fielding, Adele K. ;

Richards, Susan M. ;

Chopra, Rajesh ;

Lazarus, Hillard M. ;

Litzow, Mark R. ;

Buck, Georgina ;

Durrant, I. Jill ;

Luger, Selina M. ;

Marks, David I. ;

Franklin, Ian M. ;

McMillan, Andrew K. ;

Tallman, Martin S. ;

Rowe, Jacob M. ;

Goldstone, Anthony H. .

BLOOD, 2007, 109 (03) :944-950

[9] How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia [J].

Frey, Noelle V. ;

Luger, Selina M. .

BLOOD, 2015, 126 (05) :589-596

[10] Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma [J].

Garfall, Alfred L. ;

Maus, Marcela V. ;

Hwang, Wei-Ting ;

Lacey, Simon F. ;

Mahnke, Yolanda D. ;

Melenhorst, J. Joseph ;

Zheng, Zhaohui ;

Vogl, Dan T. ;

Cohen, Adam D. ;

Weiss, Brendan M. ;

Dengel, Karen ;

Kerr, Naseem D. S. ;

Bagg, Adam ;

Levine, Bruce L. ;

June, Carl H. ;

Stadtmauer, Edward A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (11) :1040-1047

← 1 2 3 4 →